Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study The DNA damage response (DDR) ...
Poly adenosine diphosphate-ribose polymerase inhibitors, an important class of anticancer drugs, employ synthetic lethality strategy and are particularly effective against cancers with genetic ...
We performed a pooled analysis of multiple trials of poly(ADP-ribose) polymerase inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) to investigate the efficacy of PARPi in ...
ADP-ribosylation, the attachment of ADP-ribose to proteins, is a common eukaryotic post-translational modification. It exists in two forms: mono ADP-ribosylation (MARylation), where individual units ...
Uterine sarcomas are rare, aggressive tumors with limited chemotherapy responsiveness. Poly(ADP-ribose) polymerase inhibitors (PARPis) have emerged as targeted therapies for patients with BRCA ...
Researchers from the Department of Biomedical Engineering at UNIST and the Center for Genomic Integrity at the Institute for Basic Science (IBS) have announced an advance in cancer gene therapy. Their ...
Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...
Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results